enGene Holdings (ENGN) AI Stock Analysis

• Market Cap: $677.26M
• Dividend Yield: N/A
• Average Volume (3M): 344.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.51
• Revenue Growth: N/A
• EPS Growth: -52.86%
• Country: US
• Employees: 56
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.73
• Shares Outstanding: 66,989,460
• 10 Day Avg. Volume: 129,600
• 30 Day Avg. Volume: 344,616
• PEG Ratio: 0.06
• Price to Book (P/B): 2.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.66
• Enterprise Value/Market Cap: 0.74
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -980.79
• Enterprise Value/Ebitda: -4.39
• 1Y Price Target: $26.67
• Price Target Upside: 163.80% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): -2.45
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $10.00 ▼(-1.09% Downside)
• Action: Reiterated Date: 01/24/26
• Date: Action: Reiterated 01/24/26

The score is held down primarily by weak financial performance (no revenue, large operating losses, and significant cash burn). Technicals are supportive due to a strong uptrend, but momentum appears overextended. The recent $130M financing improves funding runway, partially offsetting the weak fundamentals, while valuation remains constrained by a negative P/E and no dividend support.

Positive Factors

Conservative leverage

Modest leverage and a meaningful equity base reduce refinancing pressure and give management financial flexibility over the medium term. This structure supports continued R&D investment and partnership options, helping sustain operations while clinical milestones are pursued.

Strengthened funding runway

A $130M financing materially extends runway and lowers near-term liquidity risk, enabling continuation of clinical programs and strategic development. While dilutive, the capital infusion is a structural improvement to funding stability and supports multi-quarter program execution.

Proprietary delivery platform

A proprietary non-viral localized delivery platform and a focused lead program (bladder cancer) provide a defensible technological moat. Targeted delivery can enable differentiated safety/efficacy profiles and create durable commercialization or partnering opportunities if clinical data validate the approach.

Negative Factors

No revenue base

Zero revenue means the business relies entirely on external capital and milestones for value creation. Without commercial sales, long-term sustainability depends on successful trials or partnerships; delays or failures materially increase dilution and constrain strategic optionality.

Persistent operating losses

Large recurring operating losses reflect a high fixed-cost development model typical of pre-commercial biotech. Continued negative EBIT implies ongoing funding needs and raises execution risk; profitability remains distant until clinical success or licensing revenues materialize.

Worsening cash flow

Deepening negative operating and free cash flow indicates accelerating cash burn and dependence on financing. This structural cash consumption increases dilution risk and limits flexibility for additional programs or partnerships unless spending is curtailed or new funding sources arise.

enGene Holdings Business Overview & Revenue Model

Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

How the Company Makes Money

enGene Holdings makes money primarily through the development and commercialization of its gene therapy products. The company's revenue model includes licensing its proprietary technology to pharmaceutical partners, collaborating with research institutions for joint product development, and directly selling its therapeutic products upon regulatory approval. Key revenue streams include milestone payments and royalties from partnerships, as well as potential sales from its own product pipeline. Significant partnerships with established pharmaceutical companies enhance its market reach and contribute to its earnings by accelerating the development and commercialization processes.

enGene Holdings Financial Statement Overview

Summary

Overall fundamentals are weak: the company has $0 revenue, deeply negative EBIT, and worsening operating/free cash flow (heavy cash burn). The balance sheet is a partial offset with modest leverage, but equity declined materially and net income appears volatile and likely non-recurring in nature.

Income Statement

The income statement is weak and volatile. Revenue is consistently $0 across all annual periods, while operating profitability is deeply negative in recent years (2025 EBIT -$123.2M; 2023 EBIT -$26.1M), reflecting a high ongoing cost base typical of pre-commercial biotech. Net income swung sharply from losses (2023 -$99.9M; 2024 -$55.1M) to a large profit in 2025 (+$117.3M), suggesting earnings are being driven by non-operating or one-time items rather than sustainable core operations.

Balance Sheet

The balance sheet is relatively supportive, with modest leverage and a meaningful equity base. Debt remains moderate versus equity (debt-to-equity ~0.19 in 2025 and ~0.09 in 2024), which reduces refinancing pressure. However, equity declined materially from 2024 to 2025 ($272.6M to $167.7M), and returns to shareholders are inconsistent (ROE swings from negative in 2023–2024 to strongly positive in 2025), highlighting instability tied to earnings volatility.

Cash Flow

Cash flow quality is weak. Operating cash flow is consistently negative and worsening in absolute dollars in the latest year (2025 operating cash flow -$99.2M vs. 2024 -$48.3M), and free cash flow is also deeply negative (2025 -$100.7M). While free cash flow growth shows a positive figure in 2025, the company remains in heavy cash burn mode, implying continued dependence on external funding unless spending is reduced or revenue sources emerge.

Breakdown	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-509.00K	-323.00K	-175.00K	0.00	0.00
EBITDA	-113.80M	-52.04M	-94.77M	268.73K	47.00K
Net Income	117.30M	-55.14M	-99.92M	30.73K	-23.44M
Balance Sheet
Total Assets	221.47M	311.17M	86.96M	132.04M	131.45M
Cash, Cash Equivalents and Short-Term Investments	193.81M	238.40M	81.60M	314.15K	1.07M
Total Debt	31.80M	25.02M	9.78M	0.00	0.00
Total Liabilities	53.76M	38.56M	14.47M	4.62M	4.05M
Stockholders Equity	167.71M	272.61M	72.49M	127.42M	127.39M
Cash Flow
Free Cash Flow	-100.72M	-49.21M	-25.06M	-17.75M	-16.23M
Operating Cash Flow	-99.24M	-48.28M	-24.74M	-17.59M	-15.98M
Investing Cash Flow	-25.14M	-125.95M	-318.00K	-153.00K	-247.00K
Financing Cash Flow	1.52M	265.72M	86.15M	27.97M	22.52M

enGene Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENGN, the sentiment is Positive. The current price of 10.11 is above the 20-day moving average (MA) of 9.85, above the 50-day MA of 9.48, and above the 200-day MA of 6.50, indicating a bullish trend. The MACD of 0.15 indicates Positive momentum. The RSI at 53.39 is Neutral, neither overbought nor oversold. The STOCH value of 49.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENGN.

enGene Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CAPR	57 Neutral	$1.52B	-15.53	-107.79%	―	-52.08%	-69.35%
CTNM	54 Neutral	$560.36M	-6.80	-30.40%	―	―	-100.71%
IMRX	52 Neutral	$322.20M	-2.80	-43.75%	―	―	9.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENGN	47 Neutral	$677.26M	-4.41	-53.28%	―	―	-52.86%
REPL	47 Neutral	$631.68M	-2.14	-90.88%	―	―	-15.77%
TVRD	46 Neutral	$37.43M	-0.40	-97.61%	―	-53.67%	86.75%